



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

LEVAMLODIPINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
LEVAMLODIPINE MALEATE	CONJUPRI, LEVAMLODIPINE MALEATE	46284		GPI-10 (3400006728)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of hypertension and meet **ALL** of the following criteria?
 - The patient is 6 years of age or older
 - The patient had a trial of or contraindication to TWO generic dihydropyridine calcium channel blockers (e.g., amlodipine, felodipine, nicardipine)
 - The patient had a trial of or contraindication to TWO other antihypertensive agents in another class (e.g., hydrochlorothiazide, lisinopril, losartan)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **LEVAMLODIPINE (Conjupri)** requires the following rule(s) be met for approval:

- A. You have hypertension (high blood pressure)
- B. You are 6 years of age or older
- C. You have tried or have a contraindication (harmful for) to TWO generic dihydropyridine calcium channel blockers (such as amlodipine, felodipine, nicardipine)
- D. You have tried or have a contraindication (harmful for) to TWO other antihypertensive agents in another class (such as hydrochlorothiazide, lisinopril, losartan)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Conjupri.

REFERENCES

- Conjupri [Prescribing Information]. Hong Kong: CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 06/01/22

Created: 10/20

Client Approval: 05/22

P&T Approval: 10/20

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.